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ABSTRACT:
Neuroblastomas express increased levels of gastrin-releasing peptide receptor 
(GRP-R). However, the exact molecular mechanisms involved in GRP-R-mediated cell 
signaling in neuroblastoma growth and metastasis are unknown. Here, we report 
that focal adhesion kinase (FAK), as a critical downstream target of GRP-R, is an 
important regulator of neuroblastoma tumorigenicity. We found that FAK expression 
correlates with GRP-R expression in human neuroblastoma sections and cell lines. 
GRP-R overexpression in SK-N-SH cells increased FAK, integrin α3 and β1 expressions 
and cell migration. These cells demonstrated flatter cell morphology with broad 
lamellae, in which intense FAK expression was localized to the leading edges of 
lamellipodia. Interestingly, FAK activation was, in part, dependent on integrin α3 and 
β1 expression. Conversely, GRP-R silencing decreased FAK as well as Mycn levels in 
BE(2)-C cells, which displayed a denser cellular morphology. Importantly, rescue 
experiments in GRP-R silenced BE(2)-C cells showed FAK overexpression significantly 
enhanced cell viability and soft agar colony formation; similarly, FAK overexpression 
in SK-N-SH cells also resulted in increased cell growth. These effects were reversed 
in FAK silenced BE(2)-C cells in vitro as well as in vivo. Moreover, we evaluated 
the effect of FAK inhibition in vivo. FAK inhibitor (Y15) suppressed GRP-induced 
neuroblastoma growth and metastasis. Our results indicate that FAK is a critical 
downstream regulator of GRP-R, which mediates tumorigenesis and metastasis in 
neuroblastoma. 
INTRODUCTION 
Neuroblastoma is highly aggressive with frequent 
metastases, which contributes to overall significant 
morbidity and mortality [1]. We have shown that 
gastrin-releasing peptide receptor (GRP-R), a G-protein 
coupled receptor, is involved in neuroblastoma cell 
survival, invasive potential and metastasis [2, 3]. We 
reported that the upregulation of GRP-R increases the 
binding capacity for its ligand GRP, resulting in a faster 
constitutive neuroblastoma cellular growth rate [2]. 
Conversely, downregulation of GRP-R reversed the 
aggressive cell phenotype and inhibited liver metastases 
in vivo [3]. Therefore, GRP-R-mediated signaling 
plays critical roles in tumorigenesis and metastasis in 
neuroblastoma. However, we have yet to clearly define the 
molecular mechanisms responsible for GRP-R-mediated 
tumorigenicity.
Focal adhesion kinase (FAK), a 125-kDa 
cytoplasmic non-receptor protein tyrosine kinase, plays 
an essential role in cell adhesion and migration [4]. FAK 
is comprised of a central catalytic domain flanked by large 
N- and C-terminal non-catalytic domains. The N-terminal 
domain of FAK binds to sequences in the cytoplasmic 
domain of β-integrin subunits, thereby functioning as 
an important member of the integrin signaling pathway. 
The C-terminal region of FAK is rich in protein-protein 
interaction sites, directing FAK to newly-formed and 
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existing adhesion complexes [4]. Cancers are known 
to express FAK, which is responsible for stimulated 
cell motility, invasiveness and proliferation [5-7]. FAK 
activation is involved in various intracellular pathways, 
including GRP-mediated cell signaling [8, 9]. 
High levels of GRP-R and FAK have been reported 
in prostatic tissues from patients with advanced cancer 
and in tumorigenic cell lines [5]. One report showed 
that expression of FAK and phosphorylated (p)-FAK 
(Y397) correlates with the degree of colon cancer cell 
differentiation as well as to GRP/GRP-R co-expression 
[10]. Bombesin (BBS), an amphibian equivalent of GRP, 
induces PC-3 cell motility through FAK activation [11]. 
We and others have shown that GRP and BBS bind to 
GRP-R with high affinity to stimulate neuroblastoma cell 
growth in an autocrine and/or paracrine fashion [11, 12]. 
However, the intracellular signaling mechanisms involved 
in GRP/GRP-R-mediated FAK activation and subsequent 
neuroblastoma cell growth, motility and metastasis remain 
unclear.
In this study, we show that GRP-R and FAK 
expressions in human neuroblastoma tissues and cell 
lines correlate with tumor malignancy. Exogenous GRP 
induced FAK activation at Y397 and enhanced cell 
migration. Interestingly, GRP-R overexpression increased 
FAK, integrin expressions as well as cell migration in 
SK-N-SH cells. Conversely, GRP-R silencing resulted in 
decreased FAK and Mycn proteins in BE(2)-C cells while 
FAK overexpression in GRP-R silenced BE(2)-C cells 
rescued cell growth. Moreover, FAK overexpression alone 
led to an increase in soft agar colony formation in SK-
N-SH cells, whereas FAK silencing resulted in decreased 
colony formation in BE(2)-C cells. We also found that 
FAK silencing in BE(2)-C cells suppressed tumorigenesis 
and metastasis in vivo. Furthermore, using an intrasplenic 
murine model and bioluminescence imaging system, 
we confirmed that treatment with Y15, a FAK inhibitor, 
blocks BBS-induced neuroblastoma growth and liver 
metastases in vivo. Our results demonstrated that FAK 
correlates with GRP-R, and that it exerts oncogenic 
effects in neuroblastoma as a mediator of GRP-R signaling 
pathway. Hence, FAK may be a clinically important 
therapeutic target in the treatment of neuroblastomas.
RESULTS 
GRP-R and FAK correlated with malignant 
potential of neuroblastoma, and GRP induced FAK 
activation (Y397) and cell migration. 
We reported that an increased GRP and 
GRP-R expression is found in more undifferentiated 
neuroblastoma [12]. FAK expression has been correlated 
with advanced-stage neuroblastoma [13]. In this study, 
we wanted to determine whether GRP-R expression 
is associated with FAK in neuroblastoma. First, we 
performed immunohistochemistry to assess GRP-R 
and FAK expression in seven paraffin-embedded 
tumor sections consisting of five undifferentiated 
neuroblastomas and two ganglioneuromas. As expected, 
increased FAK expression was noted in undifferentiated 
neuroblastomas when compared to more benign phenotype 
of ganglioneuromas; its expression also correlated with 
GRP-R (Fig. 1A). But due to the limited sample size, we 
could not determine a correlation of these two protein 
markers with clinical disease staging. Next, when grown 
on soft agar, BE(2)-C cells exhibited significantly more 
colony formation (Fig. 1B), which indicates malignant 
potential. Consistent with GRP-R protein levels, we found 
higher levels of FAK protein (Fig. 1B) as well as mRNA 
(Fig. 1C) in BE(2)-C when compared to SK-N-SH cells. 
Immunofluorescence also demonstrated that BE(2)-C cells 
show more intense GRP-R and FAK expression when 
compared to SK-N-SH cells (Fig. 1D). FAK activation at 
Y397 site by GRP is well established in 293 HEK cells 
and various other cancer types [8, 11, 14]. When GRP was 
exogenously administered for 5 min, we noted a dose-
dependent increase in p-FAK levels in BE(2)-C but not 
SK-N-SH cells (Fig. 1E). Moreover, we also found that 
GRP treatment induces significant BE(2)-C cell migration 
in both transwell migration (Supplemental data; Fig. 
S1B). These results show that FAK expression correlates 
with malignant potential induced by increased GRP-R 
expression in neuroblastoma. Our results also support for 
the important role of FAK as a mediator of GRP/GRP-R 
signaling, and further validate GRP as an inducer of cell 
migration in neuroblastoma.  
GRP-R overexpression increased FAK and cell 
migration in SK-N-SH. 
To determine the positive relationship between FAK 
and GRP-R in neuroblastoma cells, we next performed 
studies using a GRP-R overexpressing SK-N-SH cell 
line established in our laboratory [2]. In figure 2A, 
GRP-R overexpressing SK-N-SH cells showed increased 
GRP-R mRNA expression but no significant increase 
of FAK mRNA (*= p <0.05 vs. SK/CON). However, 
immunoblotting showed that FAK protein is upregulated 
in GRP-R overexpressing SK-N-SH cells when compared 
to controls (Fig. 2B). Interestingly, integrin α3 and β1 
expressions were also significantly upregulated in GRP-R 
overexpressing cells (Fig. 2B). To confirm whether 
increased FAK activation in GRP-R overexpressing cells 
is dependent on these upregualted integrin expressions, 
we next performed dual silencing of integrin α3 and 
β1 (siIntegrin α3β1) in GRP-R overexpressing SK-N-
SH cells and found that siIntegrin α3β1 significantly 
decreased p-FAK expression (Fig. 2C). Additionally, to 
Oncotarget 2012; 3: 123456-15871578www.impactjournals.com/oncotarget
validate these findings and to localize FAK expression, 
we next performed immunofluorescence study. GRP-R 
overexpressing SK-N-SH cells, which have an altered 
cell morphology exhibiting a flatter shape with broad 
lamellipodial projections, showed significantly enhanced 
FAK expression at the leading edges of cells (Fig. 2D). 
Furthermore, GRP-R overexpressing SK-N-SH cells 
exhibited increased cell migration in the transwell 
plates coated with collagen type I (Fig. 2E). These 
results indicate that GRP-R regulates FAK levels post-
transcriptionally and FAK activation is regulated in part 
by integrin expressions in GRP-R overexpressing SK-N-
SH cells.
GRP-R silencing decreased FAK and cell migration 
in BE(2)-C cells. 
Next, to further validate the correlation between 
GRP-R and FAK, we used stably-transfected GRP-R 
silenced BE(2)-C cells (shGRP-R) established in our 
laboratory [3]. In figure 3A, GRP-R silenced BE(2)-C cells 
showed decreases in both GRP-R as well as FAK mRNA 
levels (*= p <0.05 vs. BE/shCON). Furthermore, we found 
that both phosphorylated and total FAK protein levels 
were decreased in shGRP-R (Fig. 3B). Interestingly, we 
also found that shGRP-R cells downregulated Mycn (Fig. 
3B), which is a well known transcription factor of FAK 
in neuroblastoma [15, 16]. Consistent with these findings, 
immunofluorescence showed significantly weaker FAK 
expression in shGRP-R when compared to control cells 
(shCON) (Fig. 3C). Moreover, the appearance of BE(2)-C 
cells changed from their typical flat and aggregated 
morphology to a small and rounder shape after transfection 
with silencing of GRP-R. Furthermore, shGRP-R cells 
exhibited decreased cell migration in the transwell plates 
coated with collagen type I (Fig. 3D). Hence, our results 
support a positive correlation between GRP-R and FAK, 
indicating that GRP-R is important in the regulation of 
FAK-induced changes in cell morphology and increased 
migration in neuroblastoma cells.
FAK regulated neuroblastoma cell growth in vitro 
and in vivo. 
In order to examine the critical role of FAK on 
neuroblastoma malignant potential, we transiently 
transfected SK-N-SH and BE(2)-C cells with FAK 
plasmid (Fig. 4A) and siRNA against FAK (siFAK) (Fig. 
4D), respectively. To validate the effects of downstream 
signaling pathways on modulating FAK expression in each 
cell line, phosphorylated and total expressions of AKT 
and ERK1/2 were examined. Interestingly, modulation of 
FAK expression led to differential expression of p-AKT 
and p-ERK (Figs. 4A, D). FAK overexpression stimulated 
phosphorylation of AKT and ERK. Conversely, FAK 
Figure 1: GRP-R and FAK expressions correlate 
to neuroblastoma malignancy and GRP-induced 
FAK activation (Y397). (A) Representative histological 
sections from human ganglioneuroma and undifferentiated 
neuroblastomas showed similar FAK (top row) and GRP-R 
(bottom row) expressions by immunohistochemistry (100× 
magnification, 20 μm bar). (B) Increased number of colony 
formation was observed in BE(2)-C cells. BE(2)-C cells 
demonstrated higher constitutive GRP-R and FAK protein levels 
when compared to SK-N-SH cells by immunoblotting. β-actin 
showed relatively equal loading. (C) A higher basal level of FAK 
mRNA was also observed in BE(2)-C cells. FAK mRNA level 
was expressed as relative copies of FAK/GAPDH (*= p <0.05 
vs. BE(2)-C). (D) More intense immunofluorescence of FAK 
and GRP-R were observed in BE(2)-C cells when compared to 
SK-N-SH cells (600× magnification). (E) Exogenous GRP for 5 
min after overnight serum starvation increased p-FAK (Y397) as 
measured by immunoblotting; increased p-FAK by 10 nM and 
100 nM of GRP in BE(2)-C was observed when compared to 
SK-N-SH cells (*= p <0.05 vs. no treated control).
Oncotarget 2012; 3: 123456-15871579www.impactjournals.com/oncotarget
silencing decreased p-AKT and p-ERK levels, hence 
suggesting a mechanism of FAK activation of PI3K and 
MEK pathways in neuroblastoma cells. We used soft 
agar colony assay to assess for anchorage-independent 
cell growth, which is a well-established indicator 
of tumorigenicity of cancer cells in vitro [17]. FAK 
overexpression showed an increased number of colonies 
by > 2.5-fold, and quite interestingly, it also resulted in 
formation of larger colonies (Fig. 4B). Furthermore, cell 
viability also increased over a time course with most 
significant increase at 96 h (Fig. 4C). In contrast, siFAK 
showed decreased number of colonies by 35%; siFAK 
resulted in fewer and smaller colonies when compared 
to siNTC (Fig. 4E). siFAK also significantly decreased 
BE(2)-C cell viability (Fig. 4F). To validate these findings 
in vivo and to further examine the metastatic potential 
of BE(2)-C cells stably-transfected with shRNA against 
either control (shCON) or FAK (shFAK), we performed 
intrasplenic injections of neuroblastoma cells in nude 
mice. Our laboratory established a murine model to 
investigate neuroblastoma metastasis, and reported 
that GRP-R silencing inhibited tumor growth and liver 
metastases in vivo [3]. The specificity of FAK silencing 
was demonstrated by immunoblotting (Fig. 4G). Six 
weeks after injections, tumor volumes of spleen and 
liver were examined. While shCON formed numerous 
large liver metastases, shFAK developed very few liver 
lesions (Fig. 4H). The average spleen and liver weight in 
the shFAK group was approximately 62% of the shCON 
group (mean value 0.08 for shCON vs. 0.05 for shFAK) 
(Fig. 4I). These results indicate that FAK silencing 
decreases malignant potential of neuroblastoma cells, thus 
providing further support for the importance of FAK as a 
regulator of neuroblastoma malignancy. 
FAK overexpression rescued GRP-R silencing-
mediated inhibition of cell growth in vitro and in 
vivo.
 To assess whether FAK is a downstream target of 
GRP-R-mediated cell signaling, we next performed rescue 
Figure 2: GRP-R overexpression increased FAK and cell migration in SK-N-SH cells. (A) Increased levels of GRP-R mRNA 
but no significant increase of FAK mRNA were observed in GRP-R overexpressing SK-N-SH cells (*= p <0.05 vs. SK/CON). (B) Increased 
FAK expression as well as integrin α3 and β1 levels in GRP-R overexpressing SK-N-SH cells were confirmed by immunoblotting. β-actin 
demonstrated relatively equal loading. (C) Dual silencing of integrin α3 and β1 (siIntegrin α3β1) in GRP-R overexpressing SK-N-SH 
cells decreased expression of p-FAK (Y397). β-actin demonstrated relatively equal loading. (D) GRP-R overexpressing SK-N-SH cells 
demonstrated altered cellular morphology to a flatter appearance along with significantly more intense FAK immunofluorescence (red 
color). Merged image indicates FAK, Tubulin (green color) and nuclei (400× magnification). A representative higher magnification image 
(enlarged box) showed intense FAK localization at the leading edges. (E) GRP-R overexpressing SK-N-SH cells migrated more in collagen 
type I-coated transwell plates when compared to the control. Representative images of DAPI staining for counting were shown (200× 
magnification) (*= p <0.05 vs. CON). 
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experiments using a FAK plasmid in shGRP-R cells in 
order to test whether FAK overexpression recovers the 
inhibitory effect of shGRP-R. Immunoblotting showed 
knockdown of GRP-R and overexpression of FAK after 
transfections (Fig. 5A). As previously reported [3], 
shGRP-R exhibited significantly reduced number of soft 
agar colony formation. FAK overexpression resulted in 
increased colony formation in both shCON and shGRP-R 
cells (Fig. 5B). FAK overexpression in shGRP-R cells 
rescued their ability to form colonies similar in value to 
that of shCON. Correlative to soft agar colony formation, 
cell viability assays demonstrated restored cell growth 
after FAK overexpression in shGRP-R cells (Fig. 5C). 
Furthermore, to demonstrate these observations in 
vivo, we used a murine model after stably-transfecting 
BE(2)-C cells with a lentiviral system of FAK plasmid. 
Specificity of each protein expression was demonstrated 
by immunoblotting (Fig. 5D). BE(2)-C cells with GRP-R 
knockdown (GC) induced fewer metastatic lesions in the 
liver when compared to control (CC), and reintroducing 
GRP-R (GG) into cells rescued the inhibitory effect 
of GC (Fig. 5E). Although FAK overexpression in GC 
(GF) did not show statistically significant effects on liver 
metastasis, the mean weight of spleen and liver in these 
mice increased by ~1.5-fold of GC (mean value 0.06 for 
GC vs. 0.09 for GF) (Fig. 5F). These findings suggest that 
FAK plays a critical role in GRP-R-induced anchorage-
independent growth. Also, as a downstream target of 
GRP-R, FAK expression, compensates, in part, for the 
inhibitory effect of GRP-R silencing in neuroblastoma. 
Taken together, our results demonstrate that FAK is an 
important mediator in the GRP/GRP-R signaling pathway.
FAK inhibitor reduced BBS induced-tumor growth 
and metastasis in vitro and in vivo. 
Previously, we have reported that BBS, an 
amphibian equivalent of GRP, promotes neuroblastoma 
tumor growth in vivo, and is an important stimulator 
of angiogenic pathway [18, 19]. Additionally, Y15 
compound, a FAK-specific inhibitor, has shown to 
decrease neuroblastoma growth in vivo [20, 21]. In this 
study, we wanted to determine whether FAK inhibition 
could block BBS-induced tumor growth and metastases 
in vivo. First of all, we found that pre-treatment with 
Y15 compound (10 μM) for 30 min failed to induce 
FAK activation at Y397 followed by GRP for 5 min after 
overnight serum starvation in BE(2)-C cells in vitro (Fig. 
6A). GRP alone induced activation of AKT and ERK1/2, 
whereas Y15 treatment attenuated GRP-induced increases 
in p-AKT and p-ERK (Fig. 6A). Interestingly, the Y15 
treatment also significantly inhibited GRP-induced colony 
formation in soft agar by > 2-fold (Fig. 6B). Based on 
Figure 3: GRP-R silencing decreased FAK and cell migration in BE(2)-C cells. (A) Decreases in both GRP-R mRNA as 
well as FAK mRNA expression were in GRP-R silenced BE(2)-C cells (*= p <0.05 vs. BE/shCON). (B) Decreased FAK and Mycn 
expressions in GRP-R silenced BE(2)-C cells (shGRP-R) was confirmed by immunoblotting. β-actin demonstrated relatively equal loading. 
(C) shGRP-R demonstrated a rounder, smaller morphology and showed weaker FAK immunofluorescence (red color) when compared to 
control cells (shCON). Merged image indicates FAK and nuclei (400× magnification). (D) shGRP-R migrated less in collagen type I-coated 
transwell plates when compared to shCON. Representative images of DAPI staining for counting were shown (200× magnification) (*= p 
<0.05 vs. shCON).
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these findings, 1 × 106 of luciferase-expressing BE(2)-C 
cells were injected into spleen in athymic nude mice. After 
three days, they were randomized into four groups: control 
(PBS vehicle), BBS (20 μg/kg/i.p./t.i.d.), Y15 (30 mg/kg/
i.p./day), and BBS plus Y15. Bioluminescence imaging 
system was used to monitor for primary tumor growth 
in spleen as well as liver metastasis. As shown in Figure 
6C, signals exhibited relatively equal intensities on day 1; 
however, by day 20, BBS significantly increased primary 
splenic tumor growth as well as liver metastases while 
a combination treatment with Y15 showed remarkable 
reduction in tumor growth and metastases. The inhibitory 
effects of Y15 in BBS-induced tumor growth were 
confirmed by luciferase activity of luciferase-expressing 
BE(2)-C cells (Fig. 6C-E) as well as by spleen and liver 
weight (Fig. 6F). Differences in luciferase activity at 
day 20 correlated with tumor weights in the liver and 
spleen. BBS increased luciferase activity by > 80-fold as 
Figure 4: FAK regulates neuroblastoma cell growth in vitro and in vivo. (A) Immunoblotting demonstrated FAK overexpression 
in SK-N-SH cells. pCMV6-XL4 was used for control. Phosphorylated and total protein levels of AKT and ERK1/2 were tested in the cells. 
β-actin demonstrated relatively equal loading. (B) FAK overexpression increased soft agar colonies by nearly 2.5-fold (*= p <0.05 vs. CON). 
(C) FAK overexpression increased SK-N-SH cell viability after 96 h (*= p <0.05 vs. CON). (D) Immunoblotting demonstrated transient 
FAK silencing (siFAK) in BE(2)-C cells. siFAK decreased phosphorylated protein levels of AKT and ERK1/2. β-actin demonstrated 
relatively equal loading. (E) siFAK inhibited colony formation by 35% compared to control (siNTC) (*= p <0.05 vs. siNTC). (F) siFAK 
significantly inhibited BE(2)-C cell viability after 96 h (*= p <0.05 vs. siNTC). (G) Immunoblotting demonstrated stable FAK silencing 
(shFAK) in BE(2)-C cells. β-actin demonstrated relatively equal loading. (H) Representative gross images of tumor from mice and H&E 
staining of liver sections (200× magnification, 50 μm bar) (I) Spleen and liver weight relative to body weight (n = 6 mice in each group; 
**= p <0.005 vs. shCON; Mann Whitney test)
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compared to controls (mean activity 5.30 × 107 photons/s 
for controls vs. 4.27 × 109 photons/s for BBS) whereas 
Y15 decreased the activity by < 110-fold as compared to 
controls (mean activity 5.30 × 107 photons/s for controls 
vs. 4.78 × 105 photons/s for Y15). More importantly, BBS 
plus Y15 combination significantly reduced luciferase 
activity when compared to BBS alone (mean activity 
4.27 × 109 photons/s for BBS vs. 2.65 × 105 photons/s for 
BBS plus Y15). Thus, our in vivo data corroborate in vitro 
findings, and further suggest that FAK is an important 
regulator in GRP/GRP-R signaling pathway and tumor 
metastasis in neuroblastoma. 
DISCUSSION
We previously demonstrated that GRP-R 
is overexpressed in malignant, advanced-stage 
neuroblastomas, and that GRP-R silencing suppresses 
tumorigenesis and metastasis in vivo [3, 12]. However, the 
exact molecular mechanisms of GPR/GRP-R regulation 
of tumor progression are yet to be delineated. In this 
study, we provide compelling evidence from cell and 
animal studies that FAK is an important mediator of 
GRP/GRP-R signaling-induced neuroblastoma growth 
and metastasis. We investigated the relationship between 
GRP-R and FAK, as well as the effect of FAK silencing 
using transfected cells and/or a pharmacologic agent on 
tumor growth in vitro and in vivo. GRP/GRP-R regulated 
FAK activation and expression, and further inhibition 
of FAK repressed GRP/GRP-R signaling involved in 
neuroblastoma progression. These results suggested that 
FAK is a critical downstream target of GRP/GRP-R, 
and therefore may be a promising therapeutic target for 
malignant neuroblastomas. 
GRP, the mammalian analogue of BBS, is a growth 
factor that promotes cell proliferation in cancer cells [22, 
23]. Specifically, GRP induces activation of FAK at Y397 
site, which is known to be critical for promoting both 
integrin- and/or growth-factor-stimulated cell migration, 
and is also a high-affinity binding site for Src homology 
2 (SH2) of the Src family kinases [24]. These known 
associations create the possibility for interaction with a 
number of different signaling and adaptor proteins. In 
the present study, we found that GRP/GRP-R signaling 
regulates FAK activation and expression. We also 
found that GRP-R expression correlates with integrin 
expressions. Thus, our findings further support published 
results that integrin and growth-factor receptor signaling 
can interact through either membrane-proximal clustering 
of the two receptor types or the activation of common 
downstream signaling pathways [25, 26]. 
Our findings corroborate the multiple tumorigenic 
functions of FAK, which are associated with various 
malignant and aggressive tumors, including ductal 
carcinomas of the breast [27], primary colorectal tumors 
and metastases [28], and endometrial carcinomas [29]. 
FAK has been used as a prognostic indicator as well as a 
marker for malignant transformation in breast carcinoma 
Figure 5: FAK overexpression in GRP-R silencing restores neuroblastoma growth. (A) Immunoblotting confirmed transient 
FAK overexpression (pCMV6-PTK2) in shGRP-R. β-actin demonstrated relatively equal loading. (B) FAK overexpression increased soft 
agar colonies in shCON and shGRP-R when compared to controls of FAK overexpression (*= p <0.05 vs. FAK vector control). (C) 
FAK overexpression in shGRP-R restored cell viability (*= p <0.05 vs. FAK vector control). (D) Immunoblotting confirmed stable FAK 
overexpression (pCDH-FAK) in shGRP-R. β-actin demonstrated relatively equal loading. (E) Representative gross images of tumor from 
mice (shCON/pCDH = CC, shGRP-R/pCDH = GC, shGRP-R/pCDH-FAK = GF, shGRP-R/pCDH-GRP-R = GG) and H&E staining of 
liver sections (200× magnification, 50 μm bar) (F) Spleen and liver weight relative to body weight (n = 4-5 mice in each group; *= p <0.05 
vs. CC, †= p <0.05 vs. GC; Mann Whitney test). 
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Figure 6: Y15, a FAK inhibitor blocks BBS-induced neuroblastoma growth and metastasis. (A) Immunoblotting confirmed 
that GRP-induced FAK activation in BE(2)-C cells was blocked by pre-treatment of Y15 (10 μM) for 30 min. Y15 treatment attenuated 
GRP-induced activation of AKT and ERK1/2. (B) GRP (100 nM) increased colony formation by ~1.2-fold whereas Y15 (10 μM) inhibited 
it by 45% compared to control; similarly Y15 also inhibited GRP-induced colony formation (*= p <0.05 vs. CON, †= p <0.05 vs. GRP). 
GRP and Y15 were added into serum media on solidified soft agar. (C) Bioluminescence images showing luciferase-expressing BE(2)-C 
cells in an intrasplenic injection murine model. Pseudocolor images from each group were adjusted to the same threshold of the day. At 
day 1, mice were imaged on their left side to detect relatively equal intensity of luminescent signal of spleen. At day 20, BBS (20 μg/kg/
i.p./t.i.d.) promoted tumor growth and liver metastases, whereas Y15 (30 mg/kg/i.p./day) showed the opposite effect, and further inhibited 
BBS-induced tumor growth and liver metastases. (D) Quantitative values of bioluminescence were measured as photon counts. Results 
were given as the mean ± SEM (n = 5-6 mice in each group; *= p <0.05 vs. CON, †= p <0.05 vs. BBS). (E) Representative bioluminescence 
images of tumor tissue extracted from the mice of each group and representative images of H&E staining to confirm metastatic foci of 
neuroblastoma cells in liver lesions (200× magnification, 50 μm bar) (F) Spleen and liver weight relative to body weight (n = 5-6 mice in 
each group; *= p <0.05 vs. CON, †= p <0.05 vs. BBS; Mann Whitney test). 
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[30]. Additionally, FAK has also been established as a 
significant component in the BBS signaling pathways in 
prostate cancer [8, 9, 11] and described to play a critical 
role in GRP-mediated morphogenesis of colon cancer 
[14]. Glover et al. [8] showed that the FAK Y397 site is 
critical for GRP-induced morphogenesis in 293 HEK cells, 
and we have shown that BBS promotes tumor growth and 
angiogenesis in neuroblastoma in vivo [18, 19]. Here, we 
show that GRP or BBS stimulates neuroblastoma cell 
migration as well as liver metastases, further supporting a 
critical tumorigenic role of GRP or BBS in neuroblastoma. 
More importantly, our results, for the first time, show 
that FAK inhibition is critical to block the BBS-induced 
tumorigenesis and metastasis in vivo, and thus, further 
indicating FAK as an important therapeutic target in the 
treatment of neuroblastomas. 
Y15 compound, 1,2,4,5-benzenetetraamine 
tetrahydrochloride, has been shown to block 
phosphorylation of FAK at Y397 in neuroblastoma 
cell lines as well as inhibit growth of Mycn-amplified 
neuroblastoma tumors in vivo [20]. In our study, we 
used Mycn-amplified I-type BE(2)-C and Mycn single 
copy N-type SK-N-SH neuroblastoma cell lines. Since, 
Mycn regulates FAK expression at the promoter level 
in neuroblastoma cells [31], we speculated that GRP-R 
signaling would affect FAK by regulating Mycn. This is 
supported by the results that showed reduced level of FAK 
mRNA in GRP-R silenced BE(2)-C cells. However, the 
molecular mechanism of GRP/GRP-R signaling regulation 
of Mycn and subsequently FAK in Mycn-amplified 
neuroblastoma cells or Mycn single copy neuroblastoma 
cells remain to be defined.
Tilghman et al. [32] noted that the loss of FAK 
resulted in marked changes in cell morphology and defects 
in leading edge formation. Similar to their findings, we 
also found that silencing of FAK by either cell transfection 
or chemical compound induced morphological changes 
analogous to the effects of silencing of GRP-R, and further 
inhibited colony formation.  Hence, we infer that GRP-R 
and FAK are essential for regulating cell morphology, 
which can associate with the oncogenic properties such 
as highly migratory, anchorage-independent phenotype 
in neuroblastoma. Therefore, a better understanding of 
GRP-R and FAK regulation may not only be of biological 
significance, but it may also provide a molecular basis for 
potential clinical applications.
In conclusion, our study demonstrates that FAK 
is a crucial regulator of GRP/GRP-R signaling in 
neuroblastoma. GRP/GRP-R regulates neuroblastoma 
cell growth, transformation and migration by correlative 
regulation of FAK. Furthermore, our results suggest 
that targeting FAK can inhibit GRP/GRP-R-mediated 
oncogenic properties. Moreover, our study demonstrates 
the roles of FAK in neuroblastoma tumorigenesis and 
metastasis in vitro and in vivo. These findings are clinically 
relevant because advanced-stage neuroblastoma is 
oftentimes refractory to current multi-modality treatment 
protocols, and effective novel therapeutic target(s) are 
highly desirable. Hence, a better understanding of the 
mechanisms involved in GRP-R/FAK-induced metastatic 
potential could provide insights into development of novel 
strategies in the treatment of aggressive, undifferentiated 
neuroblastoma. 
MATERIALS AND METHODS
Antibodies and reagents 
Primary antibodies used include GRP-R from 
Abcam, p-FAK, FAK from BD Biosciences, β-actin, 
Tubulin from Sigma-Aldrich, Mycn, p-AKT, AKT, 
p-ERK1/2, ERK1/2 from Cell Signaling Technology, 
integrin α3 and β1 from Santa Cruz Biotechnology, Alexa 
Fluor 568 and 488 from Molecular Probes. FAK (4.47) 
antibody for immunohistochemistry was from Millipore. 
GRP, BBS from Bachem, Y15 (C6H10N4·4ClH, 
1,2,4,5-benzenetetraamine tetrahydrochloride) from 
Sigma-Aldrich were used. Agarose (SeaPlaque®) was 
from Cambrex Bio Science. Cell Counting Kit-8 (CCK-8) 
was from Dojindo. Immunohistochemistry reagents were 
from Dako. FAK, integrin α3 and β1 siRNAs along with 
non-targeting scrambled sequences was from Dharmacon.
Cell culture and transfection 
Plasmids for GRP-R overexpression and silencing 
have been described [2], and pCMV6-PTK2 from 
OriGene was used for transient FAK overexpression. 
shFAK and pCDH-FAK plasmids for in vivo study were 
kindly provided by Dr. S.T. Lim (University of South 
Alabama). pMSCV-LucSh, which contains a luciferase 
and zeocin-resistance fusion gene was also kindly 
provided by Dr. Andrew M. Davidoff (St. Jude Children’s 
Research Hospital). Stably-transfected cells for GRP-R 
were established by selection with G418 at 300 μg/
ml and/or zeocin at 50 μg/ml for 2 weeks as described 
[3]. Stable populations of shFAK cells were obtained by 
lentiviral infection and puromycin selection at 2.5 μg/ml. 
Luciferase-expressing cells were established by selection 
with zeocin at 50 μg/ml. 
Quantitative real-time PCR (QRT-PCR) 
Total RNA was isolated using the RNAqueousTM 
(Ambion). Isolated RNA (1 μg) was used to 
synthesize cDNA using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). 
Primers were designed to amplify a 158-bp 
FAK fragment (BC028733.2): forward primer 
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5’-TTATTGGCCACTGTGGA TGA-3’; reverse primer 
5’-TACTCTTGCTGGAGGCTGGT-3’. GRP-R and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
primers were the same as published [33]. QRT-PCR was 
performed in the CFX96™ Real-Time PCR Detection 
Systems using SsoFast™ EvaGreen Supermix (Bio-Rad). 
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 20 
min at room temperature (RT), permeabilized with 0.1% 
Triton X-100 for 15 min and blocked with 1% BSA/PBS 
for 30 min. Cells were incubated with primary antibodies 
(1:100) for 1 h at RT, washed five times with PBS and then 
incubated with secondary antibodies (1:200) for 30 min 
at RT. The nuclei were counterstained with Vectashield 
mounting medium containing DAPI (Vector Laboratories). 
The immunofluorescence of FAK was observed under a 
fluorescent microscope (Nikon Eclipse E600).
Immunohistochemistry
Tissues were fixed in formalin for 3 days and 
embedded in paraffin wax. Paraffin-embedded sections (5 
μm) were deparaffinized in three xylene washes followed 
by a graded alcohol series, antigen retrieval performed 
with 10 mM sodium citrate buffer, and then blocked with 
blocking solution for 1 h at RT. Sections were incubated 
with primary antibodies overnight at 4°C, washed with 
PBS, incubated with secondary antibodies for 30 min at 
RT, and developed with DAB reagent. All sections were 
counterstained with hematoxylin, and then dehydrated 
with ethanol and xylene. Coverslips were mounted and 
slides observed by light microscopy.
Immunoblotting 
Whole cell lysates were collected using cell lysis 
buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% 
Triton X-100, aprotinin, leupeptin, and 1 mM sodium 
orthovanadate) supplemented with proteinase inhibitors 
(Roche). PMSF (1 mM) was added immediately prior 
to use. Protein (30 μg) was run on a SDS-PAGE gel, 
transferred onto a PVDF membrane, and probed with 
antibodies. Blots were developed using an enhanced 
chemiluminescence system (Amersham Biosciences). 
ImageJ (NIH) was used for densitometry. 
Cell viability 
Cells were seeded at a density of 3 x 103 cells in a 
96-well plate and grown for up to 4 days after transfection. 
Cell numbers were assessed using CCK-8 daily. Assay 
was performed in triplicates and the values, corresponding 
to the number of viable cells, were read at OD450 with 
the EL808 Ultra Microplate Reader (Bio Tek Instrument). 
Colony formation 
Cells were trypsinized and resuspended in media 
containing 0.4% agarose and 7.5% FBS and then 
overlaid onto a bottom layer of solidified 0.8% agarose 
in 5% serum media. SK-N-SH and BE(2)-C were plated 
at concentrations of 5x103 cells/well and 3x103 cells/
well of a 12-well plate and incubated for 5 and 3 weeks, 
respectively. Colonies were stained with 0.05% Crystal 
Violet, photographed and quantified.
Migration assay
 Transwell filters (8 μm; Corning) were coated 
on the lower side with 5 μg/ml collagen type I (BD 
Biosciences) overnight and then blocked with 2.5% BSA/
PBS for 1 h. 1 × 105 cells in serum-free media added to 
the upper and incubated for 4 h. Cells were fixed with 
4% paraformaldehyde, stained with DAPI and counted. 
Assay was performed in duplicates, and counting was 
from five randomly selected microscopic fields (200× 
magnification). 
In vivo assay 
Male athymic nude mice (4–6 weeks old) were 
maintained as described [18]. All studies were approved 
by the Institutional Animal Care and Use Committee and 
were conducted in accordance with guidelines issued by 
the NIH. BE(2)-C cells were transfected with luciferase 
alone or stably-transfected with plasmids (shCON, 
shGRP-R, shFAK and/or pCDH, pCDH-FAK). 1 × 106 
cells of 50 μl of HBSS were intrasplenically injected 
as described [3]. Mice were treated daily with 50 μl of 
control vehicle (PBS) or Y15 (30 mg/kg/day) and/or BBS 
(20 μg/kg/t.i.d.). Dosages were chosen based on previous 
results [18, 21]. Tumor growth was observed by measuring 
luciferase signal with bioluminescence imaging system 
(IVIS Lumina II, Xenogen, Caliper Life Sciences) and 
body weight was measured weekly. Mice were injected 
with D-luciferin (OZ Biosciences) subcutaneously (1 mg/
mouse in 100 μl of HBSS) before being anesthetized with 
isofluorane. Measurement of total flux (photons/sec) of the 
emitted light reflects the relative number of viable cells 
in the tumor. Data were analyzed using Xenogen Living 
Image software (version 4.1). At sacrifice, spleens and 
livers were excised, weighed and fixed in formalin for 
further analyses.
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Statistical analysis 
In vitro data represent the means ± SD. Statistical 
analyses were performed using a Student’s paired t test. 
In vivo experiments were analyzed as described [3, 18]. 
Data represent the means ± SEM. Body weight was 
analyzed using one-way ANOVA or Mann Whitney test 
with repeated measures on time. p value of <0.05 was 
considered statistically significant.
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